Artikelen

Liver cancer.

Information on current developments in both regular and alternative or complementary treatments and resources for primary liver cancer and leveruitzaaiïngen at all stages.

Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.

Food and nutrients and effect on liver cancer: Menatetrenone (= similar to vitamin K2) in operable liver cancer reduces the risk of recurrence significantly - 42.7% after 1 year and 27.3% after 3 years) and 3-year survival improves to 23 %. New meta-analysis confirms results. Article updated October 15, 2011

October 15, 2011: At the bottom I have the abstract of a recent study on effect of Menatetrenone (vitamin K2) in liver tumors located. With the same positive results from these studies shows in March 2006.

March 22, 2006: Source: SOURCE: Cancer 2006, 106:867-872

Menatetrenone (= similar to vitamin K2) reduces in operable liver cancer risk of a recurrence significantly after 1 year of 42.7% and 27.3% after three years and improved 3-year survival by 23%. We translated the full press release from Reuters about the study.

Menatetrenone significantly improves treatment of liver cancer

NEW YORK MAT 16, 2006 (Reuters Health) - For patients undergoing curative - have received curative treatment for their liver cancer (HCC) reduces Menatetrenone (a medication similar to vitamin K2) significantly improves recurrence and survival, says the results show a randomized pilot study.

Menatetrenone is an analog of vitamin K2, which previously showed antiproliferative effects against leukemia and liver cell lines give the authors state.

Dr. Toshihiko Mizuta and colleagues at the Saga Medical School, Japan, investigated the effects of Menatetrenone (similar to vitamin K2) on disease recurrence and survival in 61 patients with HCC - primary liver cancer, the surgery or percutaneous local ablation therapy ( TACE and / or RFA ) had had.

Then the recurrence of HCC occurring in Menatetrenone group was 12.5% ​​after 12 months, 39.0% after 24 months, and 64.3% after 36 months, compared with 55.2%, 83.2% and 91.6%, respectively, in the placebo group says the authors.

The final survival rates were also significantly higher in the Menatetrenone group than in the placebo group (100% vs. 96.4% after 12 months, 96.6% versus 80.9% after 24 months, and 87.0% versus 64% after 36 months), says the study report.

Menatetrenone administration was not associated with side effects, the researchers report in the February 15 edition of Cancer, and no patient discontinued the study during follow-up study period of 28.9 months median Menatetrenone was effective (beneficial) for patients independent of the basic values ​​of des-gamma-carboxy prothrombin (a possible marker of more aggressive tumors which are suppressed by administration of vitamin K2), the results show. "The results of this randomized pilot study shows that Menatetrenone possible risk of recurrence of HCC - reduces liver cancer after surgery or local ablative surgery," the authors conclude. "The effect on survival requires further studies are, however, all in all, a chemoprevention of recurrence of HCC - hepatocellular carcinoma using Menatetrenone - vit. K2 seems a promising option."

SOURCE: Cancer 2006, 106:867-872.

Menatetrenone hepatocellular carcinoma Improves Outcome

NEW YORK MAT 16, 2006 (Reuters Health) - For Patients who have received Curative treatment for hepatocellular carcinoma (HCC) recurrences and improves survival Reduces Menatetrenone, the results of a pilot study suggest.

Menatetrenone is an analog of vitamin K2, Which Has Been Shown to have antiproliferative effects against leukemia and hepatoma cell lines, the authors explain. Dr. Toshihiko Mizuta and Colleagues from Saga Medical School, Japan, Investigated the effects of disease recurrence and Menatetrenone on survival in 61 patients with HCC after Curative resection They went under or percutaneous local ablation therapy.

The cumulative incidence of HCC recurrence in the group was 12.5% ​​Menatetrenone at 12 months, 39.0% at 24 months, and 64.3% at 36 months, the authors report, compared with 55.2%, 83.2%, and 91.6%, respectively, in the placebo group. Survival rates were higher in the Menatetrenone Also group than in the placebo group (100% vs. 96.4% at 12 months, 96.6% versus 80.9% at 24 months, and 87.0% versus 64% at 36 months), the report indicates. Menatetrenone treatment was not associated with any adverse effects, the researchers report in the February 15th issue of Cancer, and no patient had been drawn from the study consistently with an average 28.9 months of follow-up. Menatetrenone was beneficial in patients regard less of the baseline level of des-gamma-carboxy prothrombin (a marker of more aggressive tumors Possible That is Suppressed by vitamin K2 administration), Indicating the results. "The results from this randomized, controlled, pilot study revealed Menatetrenone That May Possibly reducing the risk of HCC recurrence after surgical resection or local ablation Curative therapy," the authors conclude the. "The effect on survival warrants Further research, however, overall, chemotherapy or secondary prevention HCC Using Menatetrenone Appears to be a promising option."

SOURCE: Cancer 2006, 106:867-872.

Vitamin analogues in chemo prevention of hepatocellular carcinoma after resection or ablation - a systematic review and meta-analysis

Vitamin analogues in chemo prevention of hepatocellular carcinoma after resection or ablation - a systematic review and meta-analysis.